Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrenomedullin in steroid-resistant ulcerative colitis (phase 2a)
jRCT2080225159Phase 2Completed
- Sponsor
- University of Miyazaki
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing High-dose adrenomedullin with Placebo (2 arms). Primary endpoint: Clinical complete remission at 8 weeks. Started Apr 2020; status: completed.
02
Drugs
fispemifene
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080225159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225159.